Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ben George

Showing results (111-120 of 124) with videos related to

Pageof 13
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 15, 2026
Spatial Configuration of Pancreatic Cancer Is Associated with Disease Recurrence after Neoadjuvant Therapy and Curative-Intent ResectionLuis H Cisneros, Merih D Toruner, Zafar Siddiqui, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 23, 2025
A Phase II Study of Neoadjuvant GVAX and Cyclophosphamide Combined with Nivolumab and SBRT Followed by Surgery in Borderline Resectable Pancreatic AdenocarcinomaParul Agarwal, Matthew Guo, Kabeer Munjal, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|April 12, 2026
Identifying high-risk components in online adaptive RT through a multi-centre FMEA to inform clinical trial QA needsSarah O Osman, Alex Dunlop, Sophie Alexander, et al.
JAMA Surgery|March 18, 2026
AI-Derived Electronic Tumor Marker For Cancer Antigen 19-9 Nonproducers With Pancreatic Ductal AdenocarcinomaSam Z Thalji, Mohammed Aldakkak, Adhitya Ramamurthi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 20, 2020
Open-label, Phase I Study of Nivolumab Combined with <i>nab</i>-Paclitaxel Plus Gemcitabine in Advanced Pancreatic CancerZev A Wainberg, Howard S Hochster, Edward J Kim, et al.
Gastroenterology|January 27, 2024
Transcriptomic-Based Microenvironment Classification Reveals Precision Medicine Strategies for Pancreatic Ductal AdenocarcinomaBen George, Olga Kudryashova, Andrey Kravets, et al.
Cancer Research|October 24, 2025
Mutant and Wild-type RAS Crosstalk and Stoichiometric Deficiencies are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal AdenocarcinomaMandana Kamgar, G Aaron Hobbs, Raven Davidson, et al.
Biorxiv : the Preprint Server for Biology|November 24, 2025
CHIMERA-DDR: A Machine Learning Framework for Classifying Heterogeneous Mismatch-Repair and Homologous-Recombination Deficiency Patterns in Prostate CancerKomal Sharma, Divin A Wilson, Yu Wang, et al.
Journal for Immunotherapy of Cancer|January 26, 2019
Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitorsJeffrey M Conroy, Sarabjot Pabla, Mary K Nesline, et al.
Journal for Immunotherapy of Cancer|February 3, 2019
Proliferative potential and resistance to immune checkpoint blockade in lung cancer patientsSarabjot Pabla, Jeffrey M Conroy, Mary K Nesline, et al.
Pageof 13

Showing results (111-120 of 124) with videos related to

Sort By:
Pageof 13
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 15, 2026
Spatial Configuration of Pancreatic Cancer Is Associated with Disease Recurrence after Neoadjuvant Therapy and Curative-Intent ResectionLuis H Cisneros, Merih D Toruner, Zafar Siddiqui, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 23, 2025
A Phase II Study of Neoadjuvant GVAX and Cyclophosphamide Combined with Nivolumab and SBRT Followed by Surgery in Borderline Resectable Pancreatic AdenocarcinomaParul Agarwal, Matthew Guo, Kabeer Munjal, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|April 12, 2026
Identifying high-risk components in online adaptive RT through a multi-centre FMEA to inform clinical trial QA needsSarah O Osman, Alex Dunlop, Sophie Alexander, et al.
JAMA Surgery|March 18, 2026
AI-Derived Electronic Tumor Marker For Cancer Antigen 19-9 Nonproducers With Pancreatic Ductal AdenocarcinomaSam Z Thalji, Mohammed Aldakkak, Adhitya Ramamurthi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 20, 2020
Open-label, Phase I Study of Nivolumab Combined with <i>nab</i>-Paclitaxel Plus Gemcitabine in Advanced Pancreatic CancerZev A Wainberg, Howard S Hochster, Edward J Kim, et al.
Gastroenterology|January 27, 2024
Transcriptomic-Based Microenvironment Classification Reveals Precision Medicine Strategies for Pancreatic Ductal AdenocarcinomaBen George, Olga Kudryashova, Andrey Kravets, et al.
Cancer Research|October 24, 2025
Mutant and Wild-type RAS Crosstalk and Stoichiometric Deficiencies are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal AdenocarcinomaMandana Kamgar, G Aaron Hobbs, Raven Davidson, et al.
Biorxiv : the Preprint Server for Biology|November 24, 2025
CHIMERA-DDR: A Machine Learning Framework for Classifying Heterogeneous Mismatch-Repair and Homologous-Recombination Deficiency Patterns in Prostate CancerKomal Sharma, Divin A Wilson, Yu Wang, et al.
Journal for Immunotherapy of Cancer|January 26, 2019
Next generation sequencing of PD-L1 for predicting response to immune checkpoint inhibitorsJeffrey M Conroy, Sarabjot Pabla, Mary K Nesline, et al.
Journal for Immunotherapy of Cancer|February 3, 2019
Proliferative potential and resistance to immune checkpoint blockade in lung cancer patientsSarabjot Pabla, Jeffrey M Conroy, Mary K Nesline, et al.
Pageof 13